Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
13 Nov 2023
// Max Bayer FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/selecta-fuses-cartesian-reverse-merger-bolstering-finances-autoimmune-cell-therapy-goals
13 Nov 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/11/13/2779033/0/en/Selecta-Biosciences-Announces-Merger-with-Cartesian-Therapeutics.html
31 Oct 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/10/31/2770616/0/en/Selecta-Announces-Transition-of-Manufacturing-and-Clinical-Operations-of-ImmTOR-for-SEL-212-to-Commercialization-Partner-Sobi.html
17 Aug 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/08/17/2727105/0/en/Selecta-Biosciences-Reports-Second-Quarter-2023-Financial-Results-and-Updates-on-Strategic-Initiative-Designed-to-Maximize-Stockholder-Value-Associated-with-SEL-212-Economics.html
17 Aug 2023
// James Waldron FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/selecta-narrows-focus-gout-drug-freezing-investment-rest-pipeline
31 May 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/05/31/2679221/0/en/Selecta-Biosciences-Announces-Presentation-of-Data-from-Phase-3-DISSOLVE-Program-of-SEL-212-in-Chronic-Refractory-Gout-During-Late-Breaking-Session-at-the-EULAR-2023-European-Congr.html
Drugs in Development
Details:
The net proceeds will support the development of the Cartesian pipeline through the Phase 3 study of lead product candidate, Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) for the treatment of myasthenia gravis.
Lead Product(s): Descartes-08
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Cartesian Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 13, 2023
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Cartesian Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Selecta Biosciences Announces Merger with Cartesian Therapeutics
Details : The net proceeds will support the development of the Cartesian pipeline through the Phase 3 study of lead product candidate, Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) for the treatment of my...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
November 13, 2023
Details:
The combined company will focus on the development of the Cartesian pipeline through the Phase 3 study of lead product candidate, Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) for the treatment of myasthenia gravis.
Lead Product(s): Descartes-08
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Leerink Partners
Deal Size: $60.2 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 13, 2023
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Leerink Partners
Deal Size : $60.2 million
Deal Type : Private Placement
Selecta Biosciences Announces Merger with Cartesian Therapeutics
Details : The combined company will focus on the development of the Cartesian pipeline through the Phase 3 study of lead product candidate, Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) for the treatment ...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
November 13, 2023
Details:
Sobi will transition the manufacturing and development rights of ImmTOR for SEL-212 to Sobi. SEL-212, a combination of Selecta’s ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase), is in development for chronic refractory gout.
Lead Product(s): Pegadricase,ImmTOR
Therapeutic Area: Rheumatology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Enzyme
Sponsor: Swedish Orphan Biovitrum AB
Deal Size: $705.0 million Upfront Cash: $75.0 million
Deal Type: Licensing Agreement October 31, 2023
Lead Product(s) : Pegadricase,ImmTOR
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Swedish Orphan Biovitrum AB
Deal Size : $705.0 million
Deal Type : Licensing Agreement
Details : Sobi will transition the manufacturing and development rights of ImmTOR for SEL-212 to Sobi. SEL-212, a combination of Selecta’s ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase), is in development for chronic refractory g...
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : $75.0 million
October 31, 2023
Details:
SEL-302 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Methylmalonic Acidemia.
Lead Product(s): SEL-302
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: National Human Genome Research Institute
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 21, 2023
Lead Product(s) : SEL-302
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : National Human Genome Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SEL-302 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Methylmalonic Acidemia.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 21, 2023
Details:
SEL-212 (combination of ImmTOR immune tolerance platform and pegadricase) is designed to reduce serum urate levels in people with chronic refractory gout, potentially reducing harmful tissue urate deposits which causes debilitating gout flares and joint deformity.
Lead Product(s): Pegadricase,SEL-110
Therapeutic Area: Rheumatology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Enzyme
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 21, 2023
Lead Product(s) : Pegadricase,SEL-110
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
Details : SEL-212 (combination of ImmTOR immune tolerance platform and pegadricase) is designed to reduce serum urate levels in people with chronic refractory gout, potentially reducing harmful tissue urate deposits which causes debilitating gout flares and joint ...
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 21, 2023
Details:
SEL-018 (xork) is being studied as a potential next generation immunoglobulin G (IgG) protease that will be developed by Astellas for use with AT845, an investigational, adeno-associated virus (AAV)-based treatment for Late-Onset Pompe disease (LOPD) in adults.
Lead Product(s): Xork,AT845
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Antibody, Unconjugated
Sponsor: Astellas Pharma
Deal Size: $350.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement January 09, 2023
Lead Product(s) : Xork,AT845
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Astellas Pharma
Deal Size : $350.0 million
Deal Type : Licensing Agreement
Details : SEL-018 (xork) is being studied as a potential next generation immunoglobulin G (IgG) protease that will be developed by Astellas for use with AT845, an investigational, adeno-associated virus (AAV)-based treatment for Late-Onset Pompe disease (LOPD) in ...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $10.0 million
January 09, 2023
Details:
The selection of a next generation Immunoglobulin A (IgA) protease from IGAN Biosciences for its IgA nephropathy (IgAN) program, will lead Selecta Biosciences to pay IGAN Biosciences.
Lead Product(s): Undisclosed
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Recipient: IGAN Biosciences
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 14, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Recipient : IGAN Biosciences
Deal Size : $1.6 million
Deal Type : Licensing Agreement
Details : The selection of a next generation Immunoglobulin A (IgA) protease from IGAN Biosciences for its IgA nephropathy (IgAN) program, will lead Selecta Biosciences to pay IGAN Biosciences.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 14, 2022
Details:
SEL-302 is Adeno-Associated Virus (AAV) sterotype which consists of MMA-101 plus ImmTOR for the treatment of patients with methylmalonic acidemia (MMA).
Lead Product(s): SEL-302
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 11, 2022
Lead Product(s) : SEL-302
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SEL-302 is Adeno-Associated Virus (AAV) sterotype which consists of MMA-101 plus ImmTOR for the treatment of patients with methylmalonic acidemia (MMA).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 11, 2022
Details:
SEL-302 comprises ImmTOR in combination with MMA-101, and has the potential to mitigate unwanted immunogenicity to treat individuals with methylmalonic acidemia.
Lead Product(s): SEL-302
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 02, 2022
Lead Product(s) : SEL-302
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SEL-302 comprises ImmTOR in combination with MMA-101, and has the potential to mitigate unwanted immunogenicity to treat individuals with methylmalonic acidemia.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 02, 2022
Details:
The partnership leverages Genovis’ proprietary immunoglobulin G protease, IdeXork, and Selecta’s ImmTOR platform to enable the dosing of transformative gene therapies in patients with pre-existing adeno-associated virus immunity and treat IgG-mediated autoimmune diseases.
Lead Product(s): Immunoglobulin G Protease
Therapeutic Area: Immunology Brand Name: IdeXork
Study Phase: PreclinicalProduct Type: Enzyme
Recipient: Genovis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 21, 2021
Lead Product(s) : Immunoglobulin G Protease
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Recipient : Genovis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The partnership leverages Genovis’ proprietary immunoglobulin G protease, IdeXork, and Selecta’s ImmTOR platform to enable the dosing of transformative gene therapies in patients with pre-existing adeno-associated virus immunity and treat IgG-mediate...
Product Name : IdeXork
Product Type : Enzyme
Upfront Cash : Undisclosed
October 21, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Selecta Biosciences is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of Sirolimus bulk with DMF offered by Selecta Biosciences
Share 
